New drug cocktail targets hard-to-treat breast cancer
NCT ID NCT04759248
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial is testing a combination of three drugs—atezolizumab, trastuzumab, and vinorelbine—in people with HER2-positive advanced or metastatic breast cancer that has already been treated with trastuzumab and other anti-HER2 therapies. The study focuses on patients whose tumors are estrogen receptor negative or have a non-luminal genetic profile, which may be more responsive to immunotherapy. The main goal is to see how many patients have their tumors shrink or disappear.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
atezolizumab, trastuzumab, and vinorelbine
What this could lead to
If successful, this combination could offer a new treatment option for people with HER2-positive advanced breast cancer that has not responded to standard therapies.
What could go wrong
This is a small phase 2 trial with only 55 participants, so results may not apply to everyone. The drugs can cause side effects like immune reactions, nerve damage, and low blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Complejo Hospitalario Universitario A Coruña (CHUAC)
A Coruña, La Coruña, 15006, Spain
-
H. Clínico San Cecilio de Granada
Granada, Andalusia, Spain
-
Hospital Clinic de Barcelona
Barcelona, Spain
-
Hospital Clinico Universitario de Valencia
Valencia, Spain
-
Hospital General Universitario de Alicante
Alicante, Spain
-
Hospital San Pedro de Alcántara
Cáceres, Spain
-
Hospital Son Espases
Palma de Mallorca, Spain
-
Hospital Universitari Sant Joan de Reus
Reus, 43201, Spain
-
Hospital Universitari Vall d' Hebron
Barcelona, Spain
-
Hospital Universitario 12 de octubre
Madrid, Spain
-
Hospital Universitario Virgen del Rocio
Seville, Spain
-
Hospital Universitario de Canarias
Santa Cruz de Tenerife, Canary Islands, 38320, Spain
-
Hospital de León
León, 24071, Spain
-
Hospital del Mar
Barcelona, Barcelona, 08003, Spain
-
Institut Català d'Oncologia Hospitalet
L'Hospitalet de Llobregat, Barcelona, Spain